Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 17955436.
- Also identified by PMC identifier 2597352.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariate analyses, the number of DRV resistance-associated mutations depended on the number of previous protease inhibitors (PIs) administered and on amprenavir/fosamprenavir treatment. Most PI-treated patients should respond favorably to DRV-based salvage therapy.
Medical subject headings
- Drug Resistance, Multiple, Viral
- HIV Infections
- HIV-1
- Protease Inhibitors
- Sulfonamides